Clinical Trial Update: A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH [Phase 3]

View source ↗

Summary

Phase 3 long-term safety and efficacy study of danicopan added to a C5 inhibitor in paroxysmal nocturnal hemoglobinuria (PNH) is ongoing; status is active not r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Danicopan (danicopan)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Status: ACTIVE_NOT_RECRUITING